ReviewActa pharmaceutica Sinica. B2025
Application of artificial intelligence in laboratory hematology: Advances, challenges, and prospects.
Review in Acta pharmaceutica Sinica. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Putting the I in AML: Artificial Intelligence and Machine Learning in Acute Myeloid Leukemia.Cells · 2026Review
- From Method-Defined Signals to Reference Measurement Procedures: Two Decades of Mass Spectrometry-Based ProGRP Quantification.Journal of proteome research · 2026Article
- Artificial Intelligence for Personalized Management of Acute Myeloid Leukemia.Journal of personalized medicine · 2026Review
- Artificial intelligence in small tissue biopsies: diagnostic applications, histochemical integration, and methodological challenges in surgical pathology.Histochemistry and cell biology · 2026Review
- From conceptual design to translational progress: Emerging advances in intelligent microneedles for biomedical applications.Acta pharmaceutica Sinica. B · 2026Review
- Review
- Blind spots in artificial intelligence systems: poor identification of self-generated medical images-evidence-based cross-sectional study.Frontiers in medicine · 2026Article
- Advancements in bone marrow biopsy: the role of omics and artificial intelligence in hematologic diagnostics.Frontiers in medicine · 2026Review
- Immune monitoring for relapse of acute myeloid leukemia after allogeneic stem cell transplantation in clinical laboratories.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diagnosis of hematological disorders is currently established from the combined results of different tests, including those assessing morphology (M), immunophenotype (I), cytogenetics (C), and molecular biology (M) (collectively known as the MICM classification). In this workflow, most of the results are interpreted manually (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.